Allogene Therapeutics Inc

+1.08 (+3.93%)
Products, Regulatory

Allogene Therapeutics Receives Ind Clearance From The U.S. Food And Drug Administration For Allo-715 In Combination With Nirogacestat In Relapsed/Refractory Multiple Myeloma

Published: 12/23/2020 18:51 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Receives Ind Clearance From the U.S. Food and Drug Administration for Allo-715 in Combination With Nirogacestat in Relapsed/refractory Multiple Myeloma.
Allogene Therapeutics Inc - Enrollment in Cohort is Expected to Begin in Q1 of 2021 for Phase 1 Clinical Trial.
Allogene Therapeutics - Co is Sponsoring and Conducting Phase 1 Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Combination.
Allogene- Assuming All Development Costs Associated With Study,exept Expenses for Manufacturing of Nirogacestat,certain Expenses Related to Ip Rights.